News summary

Seawolf Therapeutics Debuts With $100 Million to Advance DNA-Based Therapeutics

Source: BioSpace - Funding • Published: 16 Nov 2026, 12:15

Summarized by Masters of Longevity from BioSpace - Funding.

Seawolf raised $100 million and announced a Sanofi collaboration worth up to $1.2 billion.

Seawolf Therapeutics Debuts With $100 Million to Advance DNA-Based Therapeutics
Key Takeaways
  • Seawolf raised $100 million to fund its TRIDENT DNA platform.
  • TRIDENT showed durable, nucleus-targeted protein expression in primates.
  • Sanofi collaboration was announced with up to $1.2 billion milestones.
Read the full article at BioSpace - Funding ↗

Continue exploring

Recommended MoL Picks

MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.MoL PickMOTS-c: Where the Evidence EndsStudies offer clues about ageing and metabolism. What do they actually tell us about human health—and where does expert opinion take over?MoL PickWhat Changes in the Human Hippocampus with Age?A study of 40 postmortem brains maps a midlife shift in immune cells and a wider loss of cellular and genome organisation—but it does not show how to prevent cognitive decline.